BioStock: Idogen submits clinical trial application

Last week, biotech company Idogen submitted a clinical trial application to the Swedish Medical Products Agency to initiate a clinical phase I/IIa study with the cell therapy IDO 8 in patients with haemophilia A who have developed antibodies to their treatment. Once the application has been reviewed and approved, the study can be initiated, which is expected to be in the second quarter of 2022. In order to finance the upcoming study, Idogen will be carrying out a rights issue of approximately 50.4 MSEK. 

Read the full article at biostock.se:

https://www.biostock.se/en/2021/12/idogen-submits-clinical-trial-application/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se